Trials & R&D · first seen 15h ago, updated 15h ago
STAT+: Why Gilead can’t stop talking about its ambitions in immunology
Gilead Sciences’ top executives have been emphatically bullish about the biotech’s years-long push to develop drugs for inflammatory and autoimmune diseases.
Summary from STAT News.